AstraZeneca advances three treatments across Cardiovascular, Cancer and Rare Diseases

Astrazeneca

AstraZeneca plc (LON:AZN) Baxfendy (baxdrostat) has been recommended for approval in the European Union (EU) for the treatment of adults with arterial hypertension insufficiently controlled with at least two antihypertensive medicinal products. If approved, Baxfendy will be the first and only aldosterone synthase inhibitor (ASI) in the EU, directly targeting aldosterone to address a key biological driver of elevated blood pressure.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from two pivotal Phase III trials in which Baxfendy demonstrated statistically significant and clinically meaningful reductions in seated systolic blood pressure (SBP) in patients with uncontrolled or resistant hypertension, and 24-hour average ambulatory SBP in patients with resistant hypertension.1,2

There are 1.4 billion people worldwide living with hypertension.3 Approximately 50% of people already taking two or more antihypertensive medications struggle with persistently uncontrolled hypertension.4,5 About 70 million adults across Europe have hypertension that remains uncontrolled despite treatment, putting them at increased risk for cardiovascular disease and premature death.3,6,7 Hypertension is the most prevalent and significant modifiable cardiovascular risk factor worldwide, accounting for more deaths and disability than any other modifiable risk.8-10 Elevated aldosterone levels play a central role in persistently uncontrolled hypertension and are associated with a decline in kidney function and increased cardiovascular risk.11-13

Dr. Bryan Williams, Chair of Medicine at University College London and primary investigator for BaxHTN and Bax24, said: “The strength of the research behind Baxfendy is a triumph of science and demonstrates its potential as an important new class of treatment for people in Europe living with persistently uncontrolled hypertension. Epidemiological data indicate that a 10 mmHg decrease in systolic blood pressure is associated with a roughly 20% lower risk of serious cardiovascular events like heart attack and stroke, underscoring why effective blood pressure lowering matters for people living with uncontrolled hypertension.”

Ruud Dobber, Executive Vice President and President, BioPharmaceuticals Business Unit, AstraZeneca, said: “Hypertension is often called the ‘silent killer’ and is a leading risk factor for heart attack, stroke and dementia. This positive CHMP opinion for Baxfendy marks a significant step toward bringing this potential first-in-class innovation to patients in Europe. This novel medicine reflects the strength of our pipeline across interconnected cardiovascular, renal and metabolic diseases as we deliver on our 2030 ambition to bring 20 new medicines to the world.”

In the BaxHTN Phase III trial,14 published in the New England Journal of Medicine,1 Baxfendy demonstrated statistically significant and clinically meaningful efficacy for the treatment of patients with hypertension on top of standard of care. At week 12, the absolute reduction from baseline in mean seated SBP was 15.7 mmHg (95% confidence interval [CI], -17.6 to -13.7) and the placebo-adjusted reduction was 9.8 mmHg (95% CI, -12.6 to -7.0; p<0.001) for the 2mg dose.

In the Bax24 Phase III trial,15 published in The Lancet,2 Baxfendy demonstrated statistically significant, clinically meaningful and consistent blood pressure reductions in patients with resistant hypertension who received baxdrostat 2mg or placebo on top of standard of care. At week 12, the absolute reduction from baseline in ambulatory 24-hour average SBP was 16.6 mmHg (95% CI, -18.8 to -14.3) and the placebo-adjusted reduction was 14.0 mmHg (95% CI, -17.2, -10.8; p<0.0001). Efficacy was observed throughout the 24-hour period, including early morning, when patients with hypertension are at a higher risk of cardiovascular events.16,17

Baxfendy was generally well-tolerated in the trials, with no unanticipated safety findings.

Baxfendy is approved in the US and other countries as a first-in-class ASI for adults with hypertension not adequately controlled on other therapies, with regulatory filings currently under review in other major regions, including Japan and China.

Baxfendy is a first-in-class, highly selective and potent ASI designed to lower blood pressure in a new way by specifically inhibiting the production of aldosterone,18 a hormone that raises blood pressure to unhealthy levels and increases the risk of heart and kidney problems.11-13

AstraZeneca’s Imfinzi (durvalumab) in combination with enfortumab vedotin (EV) as neoadjuvant treatment, followed by Imfinzi monotherapy as adjuvant treatment after radical cystectomy (surgery to remove the bladder), has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have refused cisplatin-based chemotherapy.

The approval was granted by the Food and Drug Administration after securing Priority Review and was based on results from the VOLGA Phase III trial which were presented during a Presidential Symposium at the 2026 European Society for Medical Oncology (ESMO) Congress and simultaneously published in The New England Journal of Medicine.

In 2026, around 16,000 patients will be treated for MIBC in the United States.1 Approximately one in four patients with bladder cancer has muscle-invasive disease, where the tumour invades the muscle wall of the bladder, without distant metastases.2,3 As many as 50% of patients are ineligible for cisplatin-based chemotherapy due to impaired renal function or comorbidities.4,5 The standard treatment for these patients has historically been radical cystectomy alone, but despite undergoing this major surgery, patients experience high rates of recurrence and have a poor prognosis.4-6

Jonathan E. Rosenberg, MD, Chief of the Genitourinary Oncology Service at the Memorial Sloan Kettering Cancer Center and member of the VOLGA Steering Committee, said: “This approval brings the first perioperative immunotherapy regimen where enfortumab vedotin is administered only in the neoadjuvant setting to patients with muscle-invasive bladder cancer who are not candidates for cisplatin-based chemotherapy. The results of VOLGA show a statistically significant and clinically meaningful improvement in both event-free and overall survival along with a manageable safety profile. Based on this, the VOLGA regimen has the potential to become a new standard of care in this curative-intent setting.”

Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit, AstraZeneca, said: “Today’s approval offers a novel Imfinzi-based regimen that almost halved the risk of disease recurrence and reduced the risk of death by 42 per cent in the VOLGA trial, allowing physicians to optimise treatment for patients in this curative-intent setting. As our third bladder cancer indication in two years, this approval reinforces Imfinzi as an immunotherapy backbone across muscle-invasive and non-muscle-invasive disease.”

In the trial, patients were treated with three cycles of Imfinzi and EV before radical cystectomy, followed by nine cycles of Imfinzi adjuvant monotherapy. In a planned interim analysis, perioperative Imfinzi plus neoadjuvant EV demonstrated a 49% reduction in the risk of disease progression, recurrence, not undergoing surgery or death versus radical cystectomy with or without approved adjuvant treatment (based on an event-free survival [EFS] hazard ratio [HR] of 0.51; 95% confidence interval [CI] 0.38-0.67; p<0.0001). Estimated median EFS was not yet reached for the Imfinzi combination versus 12.1 months for the comparator arm. An estimated 64% of patients treated with the Imfinzi combination remained alive and event-free at two years compared to 45% in the comparator arm.

Results from the key secondary endpoint of overall survival (OS) showed that the Imfinzi combination reduced the risk of death by 42% compared to the comparator arm (based on an OS HR of 0.58; 95% CI 0.40-0.83; p=0.0027). Estimated median OS was not yet reached for the Imfinzi combination or comparator arm. An estimated 78% of patients treated with the Imfinzi combination were alive at two years compared to 69% in the comparator arm.  

The safety and tolerability of Imfinzi plus EV was consistent with the known safety profiles of the individual medicines, with no new safety signals identified. Grade 3 and 4 adverse events due to any cause occurred in 64% of patients treated with the Imfinzi combination and 44% of patients in the comparator arm. Patient-reported quality of life was maintained after surgery in patients treated with the Imfinzi combination.

Regulatory applications are currently under review in the European Union (EU), Japan and several other countries based on the results of the VOLGA trial. 

Imfinzi is approved in over 50 countries for patients with cisplatin-eligible MIBC based on the NIAGARA Phase III trial. Imfinzi in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy is approved in the US, Japan and other countries for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on the POTOMAC Phase III trial. In July 2026, positive high-level results from the NILE Phase III trial showed Imfinzi plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS versus chemotherapy as 1st-line treatment for patients with PD-L1 high unresectable, locally advanced or metastatic urothelial cancer.

Alexion, AstraZeneca Rare Disease’s Klygefa (gefurulimab) has been approved in the European Union (EU) as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive. Klygefa is the first and only dual-binding nanobody C5 inhibitor, offering once-weekly subcutaneous self-administration via autoinjector.

The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and was based on positive results from the pivotal PREVAIL Phase III trial. Results from the trial showed that Klygefa met its primary endpoint, demonstrating improvement from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 compared to placebo (treatment difference: -1.6 [95% CI: -2.4, -0.8], p<0.0001). A clinically meaningful improvement was observed as early as week one, and was sustained through week 26.1

gMG is a rare autoimmune disorder characterised by reduced muscle function and severe muscle weakness.2 An estimated 82,500 people are diagnosed with gMG in Europe 5 countries (Germany, France, UK, Italy and Spain) with approximately 66,000 being AChR-positive.3

Tobias Ruck, MD, Director Department of Neurology, BG University Hospital Bergmannsheil Bochum, Ruhr-University Bochum and investigator in the trial, said: “Clinical management of gMG is complex; patient symptoms, severity and trajectory can vary widely, and early, sustained disease control is critical for improving patient-related outcomes. The PREVAIL Phase III trial demonstrated the ability of gefurulimab to deliver rapid and durable disease control starting as early as week one and lasting through one year, with the added autonomy of once-weekly subcutaneous self-administration. This approval provides an important new option for physicians and patients in the EU, offering an effective and convenient approach to managing this severe, life-long rare disease.”

Lutgarde Allard, President, European Myasthenia Gravis Association (EuMGFA), said: “gMG is a disease marked by unique presentation, uncertainty, disruption and invisibility. For people across Europe living with this rare condition, the approval of this new medicine means more choice, convenience and the potential to regain independence in daily life. This news signifies more than scientific progress; it gives us hope and demonstrates that our community’s needs are being heard.”

Marc Dunoyer, Chief Executive Officer, Alexion, said: “The approval of Klygefa in Europe marks an important milestone for the gMG community, introducing a first-of-its-kind treatment that combines the proven efficacy and safety of C5 inhibition with the flexibility of once-weekly, self-administered subcutaneous dosing. This novel dual-binding nanobody is a testament to Alexion’s pioneering legacy in complement science and commitment to developing differentiated therapies for people living with rare diseases.”

Klygefa was generally well-tolerated, and the safety profile was consistent with previous trials of C5 inhibitors eculizumab and ravulizumab in gMG.1

The data from the PREVAIL trial were presented at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session during the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2025 Annual Meeting and published in JAMA Neurology.1

Klygefa is approved in the US, Japan and other countries for certain adults with gMG. Regulatory submissions based on the PREVAIL results are under review in China and additional countries.

Share on:

Latest Company News

AstraZeneca advances three treatments across Cardiovascular, Cancer and Rare Diseases

AstraZeneca has secured a positive EU recommendation for Baxfendy for uncontrolled hypertension, US approval for an Imfinzi-based bladder cancer...

AstraZeneca Q3 revenue rises 7% to $16.2bn as core earnings increase 19%

AstraZeneca reported third-quarter revenue growth of 7% to $16.2 billion, with Core EPS rising 19% to $2.79. The pharmaceutical...

AstraZeneca invests $2bn in Summit to accelerate ivonescimab development

AstraZeneca will invest $2bn in Summit Therapeutics to accelerate the development of ivonescimab and expand its potential use in...

AstraZeneca’s Trixeo Aerosphere approved in EU for asthma

The European Commission has approved AstraZeneca’s Trixeo Aerosphere as a maintenance treatment for patients aged 12 and older whose...

AstraZeneca’s Klygefa recommended for EU approval in generalised myasthenia gravis

The EMA’s CHMP has recommended Klygefa (gefurulimab) for approval as an add-on treatment for adults with AChR antibody-positive generalised...

AstraZeneca’s Etcamah approved in US for ESR1-mutated advanced breast cancer

The FDA has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after detection of...

    Search